Eloralintide is an investigational once-weekly, selective amylin receptor agonist designed to mimic the effects of the native hormone amylin. More specific details about its mechanism of action (MOA) are still under investigation as part of the clinical study program.1,2

Eloralintide has the potential MOA to decrease calorie intake, and the effects are likely mediated by affecting satiety, or the feeling of fullness.1

The mechanisms of action for eloralintide and incretins (like tirzepatide) are different; eloralintide is a selective amylin receptor agonist, whereas tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.2

The most common adverse events were mild to moderate gastrointestinal symptoms and fatigue. The incidence of these adverse events were lower with slower dose escalation and were similar to placebo in the eloratlinlide 1 and 3 mg continueous arms.2

The MOA rationale for adverse events, like fatique, are not well understood. Fatigue will be further characterized in ongoing and future studies of eloralintide.2